webinar series
Statin’ the source of that pain: Pharmacogenomics As A Preemptive Tool
A to Z of CV Pharmacotherapy: Webinar Series
Cardiovascular disease is the most important non-communicable disease in the over-burdened healthcare landscape all over the world. Statins are one of the most highly prescribed classes of medicines globally, owing to their high efficacy in attaining low-density lipoprotein cholesterol (LDL-C) goals and thus effectively reducing onset and recurrence of cardiovascular disease. However, Statin-Associated Myopathies (SAM) have been reported to afflict up to 1/3 of all patients receiving statins, and possibly one of the biggest contributors to statin non-adherence. Unfortunately, the nocebo effect, made famous by the SAMSON trial, is rife and causes many patients to stop their statins without first considering the benefits that LDL-C lowering could confer. Genetic polymorphisms in SLCO1B1 and ABCG2 have emerged as important considerations when trying to pre-empt SAM.
In this session, the experts will take you through scenarios which known information on SLCO1B1 and ABCG2 would be useful in averting non-adherence to statins, and also to give confidence to the prescriber that the pain in the thighs is unlikely a harbinger of rhabdomyolysis.
Check the original event Section here
Watch our CLAP for this webinar by Rodrigo Alonso, How to diagnose statin-induced myopathy, here
Learning Objectives
A deep dive into the scientific background of statin pharmacogenomics and its applications.
Review of the disposition of statins and their metabolites.
What does the SLCO1B1 and ABCG2 polymorphisms lead to.
What clinicians should know about when interpreting and using lab reports of polymorphism, including how variants of unknown origin should be handled in clinical practice.
Participating Experts
Prof Doreen Tan - Moderator
Doreen Su-Yin Tan is Associate Professor, Cardiometabolic Expert lead, at the Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore. She serves as a Cardiology Specialist Pharmacist at the National University Hospital and National University Heart Centre, Singapore (NUHCS). She is an Executive Committee co-Lead and Use Case Lead for CArdiovascular DiseasE National Collaborative Enterprise (CADENCE), an Expert review panel member for Agency for Care Effectiveness Clinical Guidance for “Oral anticoagulation for atrial fibrillation”, and a Hyperlipidaemia Management Expert group member. She is also the Chair for the Pharmacy Specialist Accreditation Committee (Cardiology), Associate Program Director for the R2 Cardiology Residency Pharmacy Residency Program, Ministry of Health (Singapore), Lead for the National Metrics Drug-Related Problems and Productivity committee at the Chief Pharmacist Office, Ministry of Health (Singapore), and a Board Member at the International Society of Cardiovascular Pharmacotherapy.
Twitter: @doreen_sy
LinkedIn: linkedin.com/in/doreensytan
Dr Jasmine Luzum - Speaker
Dr. Jasmine Luzum joined the faculty at the University of Michigan in July 2016. She received her PharmD summa cum laude from the University of Pittsburgh in 2008 and her PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill Eshelman School of Pharmacy in 2013. She completed a Post-Doctoral Fellowship at the Ohio State University College of Medicine and Center for Pharmacogenomics in 2016. She became a Board-Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties and an Applied Pharmacologist by the American Board of Clinical Pharmacology in 2015. The goal of Dr. Jasmine Luzum’s research is to improve medication outcomes and disparities. She uses a variety of clinical & translational research approaches, with an emphasis on pharmacogenomics. Her research has been funded by the most prestigious sponsors, published in top journals, and presented at major conferences.
Twitter: @JasmineLuzum
LinkedIn: linkedin.com/in/jasmine-luzum-talameh-pharmd-phd-fhfsa-faha-4a360731
Dr Emma Magavern - Panelist
Dr Emma Magavern is a Clinical Pharmacology and Internal Medicine doctor who completed her PhD in pharmacogenomics at the William Harvey Research Institute, QMUL, working with Professor Sir Mark Caulfield. She completed a BA in English prior to her MD and subsequent MScs in Bioethics and Genomics. Through training in clinical medicine, humanities, genetics, and pharmacology, she has developed an interest in the scientific merits, clinical potential, and implementation challenges of pharmacogenomics. She was co-secretary of the RCP/BPS working group on pharmacogenomics and led the ESC pharmacotherapy working group pharmacogenomics position paper. She is part of the newly appointed NHS England Network of Excellence for Pharmacogenomics and a co-lead for the pharmacogenomics section of the Health Education England GeNotes initiative.
Twitter: #EmmaMagavern
Related Content
Review the related CLAP for this Webinar by Rodrigo Alonso exclusively produced for ISCP members.
Watch How to diagnose statin-induced myopathy here
Performed by:
Moderator
Doreen Tan
Speaker
Jasmine Luzum
Panelist
Emma Magavern
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.